PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS clinical trials

Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids - EFC17561 - SHORE

This study is testing a new medicine, amlitelimab, for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. It aims to see if the medicine can reduce eczema symptoms and improve quality of life.